I was astonished at how much cash they will be burning this year.Probably not unreasonable given the following plans just for their drug OCA:* NDA/MAA filing for PBC in 1H 2015 * Initiate P3, etc. for NASH in 1H 2015 * Start P2 for Biliary Atresia in 2H 2015, and * Start P1 for Fibrosis by YE 2015-JPM Slide No. 25. On the bright side of the $3.3B valuation, raising another $200M or so won't cause much dilution of existing SHs. So, now that ICPT is back on my radar, I'm mulling buying back in.... :-|